Tag: multiparametric MRI

A new review of 19 studies shows that adding artificial intelligence to biparametric MRI improves its ability to detect clinically significant prostate cancer. With high sensitivity and specificity, AI helps bpMRI approach the accuracy of more complex scans without requiring contrast agents. keep reading

For men seeking precision and quality of life, focal therapy offers a powerful alternative. By targeting tumors while sparing healthy tissue, treatments such as MRgFUS, TULSA, and Focal Laser Ablation help control prostate cancer and preserve urinary and sexual function. keep reading

Not all prostate biopsies are the same. Traditional methods can require more needles and carry higher risks. In-bore MRI guidance offers a safer, more precise alternative—helping doctors target aggressive cancers with confidence while reducing unnecessary complications. keep reading

Not all biopsies are created equal. When it comes to planning radiation treatment, real-time MRI guidance makes all the difference. Learn how this advanced approach helps doctors target cancer more precisely and reduce the risk of prostate cancer returning. keep reading

Could a simple urine test change how prostate cancer is diagnosed? Research on urine spermine suggests it may help identify men at higher risk while sparing others from unnecessary biopsies. Combined with MRI, it offers a safer path to early detection. keep reading

A European study of nearly 600 men found that negative prostate MRI results accurately predicted no cancer in 96% of cases. Over three years, most men safely avoided biopsy while being monitored, suggesting pre-biopsy MRI can reduce unnecessary procedures without added risk. keep reading

For decades, standard TRUS biopsies relied on 12+ random needles—missing aggressive cancers up to 46% of the time and increasing risks of infection. Today, real-time MRI-guided biopsies use just 2–4 precisely targeted needles, giving doctors clearer answers with fewer side effects. Discover why MRI-guided precision is changing prostate cancer diagnosis. keep reading

Gleason 3+3 prostate cancer is often considered low-risk—so low that some experts say it shouldn’t even be called cancer at all. But could a new label change how patients view their diagnosis and choices? The answer may reshape the future of prostate cancer care. keep reading

Each year, hundreds of thousands of men undergo prostate biopsies triggered by PSA results—many of them unnecessary. New research shows that combining PSA testing with MRI can more accurately identify significant cancers while sparing men from needless biopsies and the harms of overtreatment. keep reading

Delaying or skipping PSA testing can have life-threatening consequences. New data confirms more men are being diagnosed with advanced prostate cancer when it’s too late for local treatment. Annual PSA checks can make all the difference. keep reading